Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample

Impairments in social functioning are a prominent source of morbidity across many mental health disorders and contribute substantially to societal burden, yet treatments that effectively and easily improve social functioning are limited. Previous experimental and clinical research suggests that MDMA/ecstasy and classic psychedelics (psilocybin, LSD, peyote, mescaline) have prosocial effects and may reduce social difficulties; MDMA in particular has been linked to increased sociability, disinhibition, fear extinction and has shown efficacy in MDMA-assisted psychotherapy for PTSD. A meta-analysis of controlled experimental studies reported a moderate-to-large effect of MDMA on self-reported sociability-related measures. Jones and colleagues set out to examine whether lifetime use of MDMA/ecstasy and selected classic psychedelics is associated with impairments in social functioning in a large, nationally representative sample of U.S. adults. The study aimed to test for protective or harmful associations in naturalistic use data, using population survey measures of social functioning and controlling for demographic and other substance-use covariates. This investigation seeks to inform whether observed population-level associations warrant further experimental study to test causality and mechanisms.

Data came from the National Survey on Drug Use and Health (NSDUH) pooled across 2015–2019. The analytical sample comprised all adult respondents aged 18 and older (unweighted N = 214,505). The NSDUH is an interviewer‑administered, computer-assisted household survey; it does not include currently incarcerated people, active duty military, or people experiencing unsheltered homelessness. The study used publicly available de-identified data and was exempt from IRB review. Dependent variables were four NSDUH items assessing impairments in social functioning during the one month in the past year when respondents felt most depressed, anxious, or emotionally stressed: two ordinal measures (degree of difficulty interacting with strangers and degree of difficulty participating in social activities, each coded 1–4) and two binary measures (whether emotional/mental health problems kept the respondent from dealing with strangers; whether they kept the respondent from participating in social activities). Responses indicating non-engagement with strangers or social activities for reasons other than mental health were recoded as missing. Primary independent variables were lifetime (ever) use of MDMA/ecstasy (yes/no) and, as exploratory exposures, lifetime use of four classic psychedelics: psilocybin, LSD, peyote and mescaline. Covariates entered simultaneously in all models included marital status, education, sex, age, income, race/ethnicity, self-reported risky behaviour, and lifetime use of multiple other substances (PCP, cocaine, inhalants, tranquilizers, heroin, pain relievers, stimulants, sedatives and marijuana). These demographic and substance-use covariates were selected to reduce confounding and to align with prior population-based studies. Analyses accounted for the NSDUH complex survey design using the Survey package in R (version 4.1.2) and applied survey weights. Descriptive statistics were generated with gtsummary, and chi-squared tests compared demographic distributions by MDMA use status. Multivariable ordinal regression was used for the two ordinal outcomes and multivariable logistic regression for the two binary outcomes; all independent variables and covariates were entered simultaneously. Approximately 0.5% of responses were omitted due to missing data. The authors state the large sample provided adequate power for the regression models.

Demographic comparisons showed that respondents reporting lifetime MDMA/ecstasy use were more often never married, younger, male, Non-Hispanic White, more formally educated, and more likely to endorse risky behaviour compared with non-users. In multivariable models adjusted for the listed covariates and survey design, lifetime MDMA/ecstasy use was associated with reduced odds for three of four social‑functioning outcomes. Specifically, MDMA use was associated with lower odds of reporting greater difficulty dealing with people not known well (adjusted odds ratio, aOR 0.92; 95% CI 0.87–0.97), greater difficulty participating in social activities (aOR 0.90; 95% CI 0.85–0.95), and being prevented from engaging in social activities due to emotional or mental health problems (aOR 0.84; 95% CI 0.71–0.99). MDMA use was not associated with the binary outcome of being prevented from interacting with strangers. Among classic psychedelics, lifetime mescaline use was associated with lowered odds of difficulty dealing with strangers (aOR 0.85; 95% CI 0.76–0.95). By contrast, lifetime LSD use was associated with increased odds of two outcomes: difficulty dealing with strangers (aOR 1.13; 95% CI 1.06–1.20) and difficulty participating in social activities (aOR 1.11; 95% CI 1.05–1.17). The authors report that other substances either showed no association or were linked to increased odds of social impairment. The analyses omitted about 0.5% of responses for missing data; no additional sensitivity analyses are reported in the extracted text.

Jones and colleagues interpret the principal finding—that lifetime MDMA/ecstasy use is associated with lower odds of several measures of social impairment—as consistent with prior experimental and clinical literature indicating MDMA has prosocial effects. They present multiple possible explanations without asserting causality. One class of explanations involves third‑variable differences: pre-existing traits such as higher extraversion, particular political or spiritual orientations, or other selection factors may make some people both more likely to use MDMA or mescaline and less likely to experience social impairment. The authors also discuss putative pharmacological and neurobiological mechanisms that could plausibly link MDMA or mescaline use to improved social functioning. For MDMA, mechanisms reviewed include effects on serotonergic and dopaminergic systems, promotion of oxytocin release, reduced amygdala reactivity to social threat cues, increased social motivation, enhanced attention and reward responses to positive social stimuli, and acute increases in emotional empathy documented in controlled trials. For mescaline and classic psychedelics more broadly, potential mechanisms centre on 5‑HT2A receptor agonism, dampened amygdala responses to negative facial expressions and a reported increase in a felt sense of interconnectedness following psychedelic experiences, which might foster prosocial behaviour. The discussion emphasises several limitations. The cross-sectional NSDUH data preclude causal inference and do not establish temporal precedence; longitudinal studies and randomized controlled trials are needed. The survey omits certain populations (incarcerated people, active duty military, unsheltered homeless), and residual confounding remains possible despite adjustment for demographic and substance-use covariates. Naturalistic measures of lifetime use do not capture dose, frequency, purity or context of use; unknown product purity could weaken pharmacological interpretations. The authors note potential harms: MDMA and classic psychedelics can produce acute adverse reactions and, in some reports, longer-term harms including neurotoxicity or increased psychosis risk; such harms may partly explain why LSD was associated with increased odds of social impairment in the present analyses. Multicollinearity among correlated covariates is acknowledged as a potential issue, though the large sample size may mitigate its impact. Finally, the lifetime use variables do not allow assessment of frequency or timing relative to onset of social difficulties. In light of these caveats, the authors recommend experimental and longitudinal research to test causality, clarify mechanisms, and delineate conditions under which these substances might support or harm social functioning. They suggest randomized controlled trials using pure compounds and more granular measurement of use and outcomes to advance understanding.

Using nationally representative survey data from 2015–2019, the study found that lifetime MDMA/ecstasy use was associated with lowered odds on the majority of assessed social‑functioning impairment outcomes, and lifetime mescaline use was associated with lowered odds of difficulty dealing with strangers. By contrast, lifetime LSD use was associated with increased odds of two social‑impairment outcomes. The authors stress that these cross-sectional associations do not demonstrate causality but argue the findings support further experimental work to determine whether MDMA, mescaline or related interventions can support social functioning and to clarify potential risks.